

Financial Tear Sheet


Aduro is a clinical-stage cancer immunotherapy company with three products currently in human trials. The company's lead candidate – an immunotherapy regimen combining our proprietary CRS-207 with GVAX Pancreas – is targeting metastatic pancreatic cancer and has received Breakthrough Therapy designation from the US Food and Drug Administration.

Stock Quote

ADRO (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$9.68
Change (%)	+ 0.18 (1.89%)
Volume	192,037

Data as of October 17, 2017 1:10 p.m. ET
 Minimum 20 minute delay
[Refresh quote](#)

Stock Chart



Press Releases

October 17, 2017

Aduro Biotech Announces Presentation of Phase 1 Data for LADD-based Immunotherapy at World Conference on Lung Cancer

October 09, 2017

Aduro Biotech Announces Upcoming Data Presentations at the Society for Immunotherapy of Cancer's 32nd Annual Meeting

Events & Presentations

There are currently no events scheduled.

Data Provided by Thomson Reuters